New path to potential treatments for researchers in advanced prostate CancerScienceDaily (July 25, 2011) UT Southwestern Medical Center have reduced the potential targets of drug for advanced prostate cancer, proving that advanced tumors are driven by a different path, hormone that was thought previously.See also:Health & MedicineReplacement therapy of prostate cancer CancerMen HealthProstate HealthLungreferenceCancerCancerBreast MetastasisTestosteroneTumor suppressor geneHormone
While testosterone is generally known to stimulate the growth of the disease, advanced prostate cancer that is resistant to standard hormonal therapy is actually driven by a path that bypasses the male hormone, said Dr. Nima Sharifi, Assistant Professor of internal medicine and senior author of the study in the Proceedings of the National Academy of Sciences.
?Our results will change the framework for people to think about this disease,? said Dr. Sharifi, a researcher at the Harold c. Simmons Comprehensive Cancer Center at UT Southwestern. ?The general belief is that the cancer will accelerate through testosterone when, in fact, the route goes around the most powerful hormone. We have found the existence of this pathway in both models and patients have shown that these tumors resistant are clearly driven by this via other. ?
Prostate cancer is the most common cancer in men and trails only lung cancer as a major cause of cancer death for men in the United States. Some 220,000 men are diagnosed with the disease each year; 32,000 develop metastatic form-the current focus of the study-and die from it.
In cases of advanced prostate cancer, testosterone, driving the disease is converted into a more powerful hormone that accelerates the growth of the tumor. The standard treatment was to deplete the tumors, but eventually become resistant to depletion because they make their own hormone androgen, or male hormone testosterone.
In this study, UT Southwestern scientists analyzed lines of cells of prostate cancer, mouse models and fresh tumor tissue from patients. The results suggest that potential drug therapies require an enzyme responsible for the production of hormones before the target process.
?This now suggests that a potential drug target is a step upstream in the street,? said Dr. Sharifi. ?This can be thought of as a map of the proper way for the creation of graphs. You understand how the river flows first you can block the River. ?
The results will also help researchers develop accurate biomarkers of response and resistance to hormonal therapies, which ultimately will help identify why and how prostate cancer tumors become resistant, he said.
The study was supported by the Howard Hughes Medical Institute, the Prostate Cancer Foundation, the u.s. Army Medical Research and Materiel Command; the Burroughs Wellcome Fund and Charles a DLL. and Elizabeth Ann Sanders Chair in translational research.
Other UT Southwestern researchers in the study participants were lead author Dr. Chang Kai-Hsiung, post-doctoral researcher; Dr. Rui Li, a research assistant in internal medicine; Mahboubeh Papri-Zareei, research associate; Dr. Lori Watumull, Professor of Radiology; Dr. Daniel Yan Zhao, Associate Professor of clinical sciences and Simmons Cancer Center; and Dr. Richard j. Auchus, former Professor of internal medicine.
E-mail or share this story:
paz de la huerta jpm us mint insidious jonah hill cosmopolitan numb
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.